T 1714/17 of 22.02.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T171417.20220222
- Date of decision
- 22 February 2022
- Case number
- T 1714/17
- Online on
- 24 June 2022
- Petition for review of
- -
- Application number
- 10182249.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of HIF alpha stabilizers for enhancing erythropoiesis
- Applicant name
- Fibrogen, Inc.
- Opponent name
- Glaxo Group Limited
Akebia Therapeutics, Inc.
Bayer Intellectual Property GmbH/Bayer Pharma
Aktiengesellschaft/Bayer Animal Health GmbH - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)
- Keywords
- Amendments - added subject-matter (yes)
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.